Downregulation of miR-29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma
- PDF / 664,753 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 196 Views
RESEARCH
Open Access
Downregulation of miR-29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma Ruihua Fang1, Yongjin Huang1, Jinghua Xie1, Jianzhong Zhang2 and Xiaobin Ji1*
Abstract Background: Laryngeal squamous cell carcinoma (LSCC) is considered to be a common malignancy of the head and neck with poor prognosis for its late diagnosis, metastasis and recurrence. Growing evidence demonstrates that the dysregulation of miR-29c-3p (microRNA-29c-3p) plays an important role in various tumor processes. Our study investigates the expression of miR-29c-3p in LSCC and analyzes the correlation of its dysregulation with clinicopathologic parameters and prognosis. Methods: The expression of hsa-miR-29c-3p in LSCC tissues and the adjacent normal laryngeal tissues was detected in 96 LSCC formalin-fixed paraffin-embedded tissues by quantitative real-time PCR (qRT-PCR). The SPSS statistical software package (17.0) was used to analyze the associations between miR-29c-3p expressions and various clinicopathological characteristics. The overall survival (OS) was analyzed by the Kaplan-Meier method and log-rank test, and we analyzed the independent factor of prognosis by Cox proportional hazard analysis. Results: A downregulation of miR-29c-3p expression in LSCC was significantly correlated with smoking index, tumor size, tumor site, differentiation, T classification, TNM stage, and lymph node metastasis (P < 0.05), but there was no correlation with age and alcohol consumption (P > 0.05). In the multivariate survival analysis, low miR-29c-3p expression was associated with shorter overall survival (P < 0.05). Furthermore, miR-29c expression was an independent prognostic factor for laryngeal cancer patients. Conclusions: MiR-29c-3p has different expression levels at different stages of tumor progression, suggesting that miR-29c-3p may be a promising biomarker for evaluating the progression of LSCC and the prognosis of patients with LSCC. MiR-29c-3p can also be a novel molecular target for anti-laryngeal cancer therapy. Keywords: Laryngeal squamous cell carcinoma, Prognosis, Biomarker, MicroRNA, MiR-29c-3p
Introduction Laryngeal squamous cell carcinoma (LSCC), as the most common histopathological type of laryngeal cancer, is the second-most common malignancy of the head and neck [1, 2]. According to studies, almost 3650 people died from LSCC worldwide in 2012, concomitantly with the increasing incidence and mortality of LSCC year-by-year [3]. At present, surgery, radiotherapy and chemotherapy are the main treatments for LSCC, but these treatments cannot * Correspondence: [email protected] 1 Department of Otolaryngology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong, People’s Republic of China Full list of author information is available at the end of the article
meet the requirements for reducing the morbidity and mortality of LSCC. Moreover, the 5-year survival rate of advanced patients was less than 50%, mainly due to metastasis and recurre
Data Loading...
